BioMed Research International

BioMed Research International / 2017 / Article
Special Issue

Molecular and Cellular Mechanisms of Neuroinflammation

View this Special Issue

Research Article | Open Access

Volume 2017 |Article ID 3706018 | 10 pages |

Markers of Alzheimer’s Disease in Primary Visual Cortex in Normal Aging in Mice

Academic Editor: Anna Di Vito
Received04 Jun 2017
Accepted09 Aug 2017
Published12 Sep 2017


Aging is the principal risk factor for the development of Alzheimer’s disease (AD). The hallmarks of AD are accumulation of the amyloid-β peptide 1–42 (Aβ42) and abnormal hyperphosphorylation of Tau (p-Tau) protein in different areas of the brain and, more recently reported, in the visual cortex. Recently, Aβ42 peptide overproduction has been involved in visual loss. Similar to AD, in normal aging, there is a significant amyloid deposition related to the overactivation of the aforementioned mechanisms. However, the mechanisms associated with visual loss secondary to age-induced visual cortex affectation are not completely understood. Young and aged mice were used as model to analyze the presence of Aβ42, p-Tau, glial-acidic fibrillary protein (GFAP), and presenilin-2, one of the main enzymes involved in Aβ42 production. Our results show a significant increase of Aβ42 deposition in aged mice in the following cells and/or tissues: endothelial cells and blood vessels and neurons of the visual cortex; they also show an increase of the expression of GFAP and presenilin-2 in this region. These results provide a comprehensive framework for the role of Aβ42 in visual loss due to inflammation present with aging and offer some clues for fruitful avenues for the study of healthy aging.

1. Introduction

Traditionally, the aging population has been associated with developed countries, but currently two-thirds of the world’s oldest persons live in developing countries, where the elderly population is growing faster than in developed regions.

AD is the most common cause of dementia in older people, and it is estimated that 27 million people are affected worldwide [1, 2]. As the life expectancy of the population increases, the number of affected individuals is predicted to present a threefold increase by 2050 [2, 3]. Different risk factors have been associated with the development of AD, such as environmental, dietary, and pathological factors, altered glucose metabolism, chronic inflammation, gender, and oxidative stress. Nevertheless, age continues to be the main risk factor for AD, although early-onset disease can occur before the age of 60 years [4, 5].

AD is a paradigm of a neurodegenerative disorder that is caused by the detrimental progression of age-dependent loss of cognitive function. The hallmarks of this disease are accumulation of amyloid aggregates (also known as amyloid plaques), principally constituted by abnormal local deposits of Aβ42 in the extracellular brain parenchyma and the hippocampus, as well as the formation of neurofibrillary tangles within the neurons in the aforementioned regions [6]. These neurofibrillary tangles consist of cross-linked protein strands that generate a double helix structure; the principal component of these tangles is the pathologically hyperphosphorylated Tau protein [7].

The production of Aβ, a critical event in AD, results from the cleavage of the amyloid precursor protein (APP), whose levels are high in AD. This peptide is toxic and induces several detrimental effects on cells, like cell membrane disruption, excessive production of reactive oxygen species, interactions with several proteins that affect their normal function, synaptic failure, chronic local inflammation, glial hyperactivity, and cell death [8]. These changes have been studied and identified mainly in brain areas such as entorhinal, prefrontal, and visual cortices, hippocampus, and olfactory bulb.

In addition, it has been reported that AD patients lose certain visual functions that are not correlated to structural damage of the eye but with loss of neurological function. Aβ42 peptide toxicity has been related to several disrupted molecular mechanisms in normal vision; for example, inhibition of long-term potentiation and cognitive processes [9, 10] increases the proinflammatory effects in the occipital visual cortex and induces gliosis and apoptosis among other toxic effects. These alterations have been correlated with ophthalmic disorders such as age-related macular degeneration (AMD) and glaucoma [1113]. However, there is not enough information about these pathological changes in the visual cortex during normal aging.

Aging is accompanied by chronic inflammation, demonstrated by the increase of inflammatory mediators such as cytokines and oxidative stress markers and chronic antigenic stress and influenced by the genetic background [1416]. Chronic inflammation appears to be involved in the pathogenesis of some age-related diseases such as AD, atherosclerosis, diabetes, age-related macular degeneration, and cancer [17, 18]. As in Alzheimer’s disease, aging is also characterized by the accumulation of Aβ42 in “inflammaging,” a term used to highlight the importance of inflammation in many age-associated diseases [19]; as previously mentioned, the presence of Aβ42 is associated with vision loss. The presence of multiple Aβ42 reservoirs in the eye (especially in the retina and the optic nerve) induces different pathologies that lead to potentially blinding disorders [20]. However, the presence of Aβ42 in the visual cortex and the role it plays in vision loss, related to normal aging, have not been described.

Brains of 4-month-old and 25-month-old C57BL/6J mice were used as an aging model. Visual cortices (VC) were analyzed to evaluate whether an AD-like pathology develops during normal aging in this area.

Our results demonstrated intracellular accumulation of Aβ42, Aβ42 deposition in blood vessels, and disturbances in the pattern of p-Tau protein distribution in the VC of 25-month-old mice. This murine model also showed overexpression of the enzymes involved in the production of Aβ42 and an increase in the number of astrocytes expressing GFAP protein in the aged mice compared to the young ones.

2. Materials and Methods

2.1. Animal and Animal Care

Young (4-month-old and 25-month-old) male C57BL/6J mice were maintained on a 12-hour light/dark cycle in a temperature-controlled room, within a clean air box, and food was provided ad libitum (NutriCubo, Purina, USA). The animals were maintained and treated in accordance with the NORMA Oficial Mexicana NOM-036-SSA2-2002, the National Institutes of Health Guidelines for Animal Treatment, and the Ethics Committee of the Asociación para Evitar la Ceguera en México, “Hospital Dr. Luis Sanchez Bulnes” IAP.

2.2. General Procedure

Mice were randomly separated into two experimental groups ( per group). Group 1 was composed of 4-month-old animals and group 2 was composed of 25-month-old mice.

The visual cortices of control and aged mice were obtained for IMHQ assays. Briefly, six animals from each group were transcardially perfused with 4% paraformaldehyde (Sigma-Aldrich Chemie, Germany) in 0.1 M phosphate buffer (J.T. Baker, NJ; PB, Tecsiquim; pH 7.4) for the immunohistochemistry assays. Male 4-month-old and 25-month-old C57BL/6J mice were evaluated in the study. Animals were perfused transcardially with phosphate-buffered saline (PBS) and 4% (w/v) paraformaldehyde under sedation. The brains were postfixed in 4% paraformaldehyde for 20 h and immersed in a 30% sucrose solution (w/v) in PBS for 24 h.

Coronal sections (20 μm) from visual cortex were cut on a freezing microtome (Leica CM3050s) and mounted serially. Slides were used for immunofluorescence detection.

2.3. Immunohistochemistry and Immunofluorescence

Rabbit monoclonal anti-Aβ42 antibody (obtained from Abcam, MA, USA) was used to detect the Aβ42 peptide. Goat polyclonal anti-GFAP and rabbit polyclonal anti-p-Tau and rabbit anti-presenilin-2 (PS2) antibodies were from Santa Cruz Biotechnology (CA, USA). Alexa Fluor 594 goat anti-rabbit IgG (H+L), Alexa Fluor 488 mouse anti-goat IgG (H+L), Alexa Fluor 488 goat anti-rabbit IgG (H+L), and Alexa Fluor 594 mouse anti-goat IgG (H+L) were from Molecular Probes, OR, USA.

For the double immunofluorescence (IF) assays, rabbit monoclonal anti-Aβ42/goat polyclonal anti-p-Tau (dilution 1 : 100) antibodies were used and visualized with Alexa Fluor 594 goat anti-rabbit IgG (H+L) and Alexa Fluor 488 mouse anti-goat IgG (H+L). Besides, rabbit monoclonal anti-PS2/goat polyclonal anti-p-Tau (dilution 1 : 100) antibodies were used and visualized with Alexa Fluor 488 goat anti-rabbit IgG (H+L) and Alexa Fluor 594 mouse anti-goat IgG (H+L). Samples were mounted onto glass slides in VECTASHIELD Medium (Vector Laboratories, Burlingame, CA, USA) containing DAPI. Representative brain sections from each group were processed in parallel next; these sections were examined with an Olympus BX41 Microscope (Japan) and photographed with an Evolution-QImaging Digital Camera Kit (Media Cybernetics, Rockville, MD, USA) for DAB reaction and the double IF assays were observed through a Leica DM-LS epifluorescence microscope at 40x and 100x (Leica Microsystems, Wetzlar, GmbH, Germany). The fluorochromes were visualized with their specific filters and analyzed in three channels.

2.3.1. Image Analysis

Fluorescence pixel intensities were measured in several regions of interest (ROIs) within each image using ImageJ. Average pixel intensities were calculated from five ROIs for measurements in different regions from each image. The measures were realized in six animals per time point. All signal intensities were background-subtracted from the average of three.

2.3.2. Statistical Analysis

All of the data are expressed as mean Chi-square for trends and Fisher’s exact tests were used for multiple comparisons. Prism GraphPad software was used (Systat Software, Inc., Point Richmond, CA, USA).

3. Results

We studied the deposition of Aβ42, changes in Tau expression patterns, GFAP overexpression, and the enzymes involved in the production of the Aβ42 peptide in the visual cortex of 4-month-old (4 M) and 25-month-old (25 M) aged symptomatic mice (C57BL/6J WT). To evaluate the overproduction and accumulation of the Aβ42 peptide in the VC, we performed double immunofluorescence assays in brain sections derived from control (4 M) and aged mice (25 M). The double IF assays showed qualitative increases in the intracellular accumulation and blood vessel deposition of Aβ42 (Figures 1 and 2) and an increase in its expression, as well as a change in p-Tau’s distribution in the VC (Figures 1, 2, and 3) of 25 M aged mice.

In order to confirm Aβ42 deposition in blood vessels, we repeated the IF to detect Aβ42 accumulation in 4 M and 25 M aged mice. Again, there is an increase of Aβ42 in blood vessels of 25 M old mice (Figure 2).

The Aβ42 peptide is a product of the proteolytic cleavage of amyloid precursor protein (APP). APP’s cleavage is done first by beta-secretase, followed by a second cleavage by the gamma-secretase complex. This complex is a multisubunit protease comprised of four components: presenilin-1 and presenilin-2 (PS1 and PS2, resp.), nicastrin, anterior pharynx defective-1 (APH-1), and presenilin enhancer 2 (PEN-2). Among these proteins, PS2 is a transmembranal protein and it has been confirmed as the main enzyme involved in the production of Aβ42 in AD. To evaluate changes in PS2 expression which could be related to the increase in the production of Aβ42, we performed IF assays in the same aging model. In these assays, because PS2 is a membranal protein (as mentioned before), we decided to use p-Tau to mark microtubules to identify the localization of PS2.

As shown in Figure 3, there is an increase of PS2 expression and there are changes in the expression pattern of this enzyme in the VC of aged mice compared to the VC of young mice. Interestingly, we observed changes in the localization of p-Tau protein in aged mice (white arrows in Figure 3).

As shown in Figure 3, there is an increase of PS2 expression and there are changes in the expression pattern of this enzyme in the VC of aged mice compared to the VC of young mice. Interestingly, we observed changes in the localization of p-Tau protein in aged mice (white arrows in Figure 3).

To evaluate whether Aβ42 deposition induces an inflammatory response in aged mice, we performed IF assays to detect astrocytes using a GFAP antibody. GFAP is a commonly used marker for astrocytes, and it has been related to brain inflammation and to the proper functioning of the blood-brain barrier in health. In this aging model, we observed an increase in the number of astrocytes positive to GFAP in 25 M mice (Figure 4). Besides, there were large numbers of astrocytes associated with blood vessels in aged mice.

Finally, to demonstrate these results in a semiquantitative manner, we performed fluorescence intensity quantification on every protein or peptide studied in this report.

As shown in Figure 5, we observed a statistically significant increase in the intracellular Aβ42 peptide (a), p-Tau (b), PS2 (c), and GFAP (d) in the VC of aged mice.

4. Discussion

In the present study, we demonstrated that, during normal aging, in mice, there is an increase of AD-like pathological changes, like intracellular accumulation and blood vessel deposition of Aβ42 in the VC; these increases were correlated with significant overexpression of one member of the gamma-secretase complex (PS2). Besides, GFAP, a common marker for astrocytes, showed an increase in its expression, and the number of GFAP-positive astrocytes also increased, indicating the activation of immunological responses in aged brains.

AD is a neurodegenerative disease with a complex and progressive pathological phenotype that is initially characterized by hypometabolism and impaired synaptic function and, subsequently, by pathological burden [21]. The Aβ42 peptide is the pathological hallmark of AD produced by the sequential cleavage of APP by β-secretase and the gamma-secretase complex. In contrast, the activation of -secretase leads to nonamyloidogenic processing of APP and the generation of truncated nontoxic sAPPa fragments [5, 22, 23]. Neurofibrillary tangles formed by the pathological hyperphosphorylation of Tau protein, an associated-microtubule protein that helps to stabilize microtubules, are the other AD hallmark.

The results presented herein show similar AD pathologic changes and, importantly, this model lacks other factors that could be inducing this pathology. It is important to mention that the amino acid sequence of the Aβ42 peptide in mice does not form amyloid plaques. However, our results indicate an increase of intracellular Aβ42 in the VC of aged mice which could be related to the increased expression of PS2, the main enzyme associated with Aβ42 production in AD [24, 25], and supported by previous studies that have shown that all the components of the gamma-secretase complex increase under stressful conditions, as in AD [26].

It has been reported that Aβ42 can bind to a great number of proteins and to extracellular and intracellular macromolecules that affect normal neuronal function due to increases in the production of hydrogen peroxide, induction of oxidative stress, disturbances in Ca2+ homeostasis, and mitochondrial dysfunction (promoting the opening of the membrane permeability transition (MPT) pores or disruption of neuronal signal transduction pathways in AD [13, 19, 2730]); however, it is not known whether Aβ42 accumulation in the VC activates these pathological processes and, as a consequence, they are affecting normal vision. Our results showed an increase of p-Tau, another hallmark of AD. It has been demonstrated that an abnormal increase in p-Tau affects the normal functioning of microtubules, impairs intracellular communication, and, finally, induces cell death [31, 32]. As we observed in Figures 1 and 2, p-Tau not only increases its expression but also shows a change of its distribution and localization, suggesting that there may be changes in its intracellular transport in aged mice. More experiments need to be performed to evaluate the impact of this differential expression and localization of p-Tau in the VC during aging.

AD represents a chronic inflammatory state caused mainly by the presence of the Aβ42 peptide. It has been broadly reported that there is an overreactivity of immune cells, such as astrocytes and microglia, during normal aging and AD [33]. Our results show that some GFAP-positive astrocytes are associated mainly with blood vessels in aged mice, and quantification of GFAP reveals that glial response is also prominent in the VC, as observed in AD. This could be relevant, because disruption of the blood-brain barrier in AD and activation of proinflammatory mechanisms (like oxidative stress) due to the presence of Aβ42 have been previously reported. Interestingly, the Aβ42 peptide accumulates in blood vessels in 25 M old mice. This could suggest that these factors are related, and the presence of growing numbers of astrocytes in blood vessels is a protective response to avoid or repair blood-brain barrier damage caused by the Aβ42 peptide’s presence in the aged visual cortex.

There are several inflammatory factors in the aging brain which originate from microglia and astrocytes, as they adopt a senescence-associated secretory phenotype [19, 34]. Some aging astrocytes release more cytokines, which is consistent with the aforementioned phenotype [35]. However, more studies are needed to demonstrate the production levels of proinflammatory cytokines in the visual cortex of aged mice. Together, these events contribute to neuronal dysfunction in primary visual areas, supposedly protected from beta-amyloid deposition [36].

In another way, in order to discuss the translation of our findings and their application in human, it is necessary to mention some interesting points about the different animal models used in aging and AD.

The simplest and best model of aging is an old organism. Mouse is an attractive model for studying mammalian biology due to the genetic manageability of its genome, ease of breeding, and the large amount of available baseline phenotypes; they are relatively economical to maintain for long-term aging studies and, more importantly, they are similar to humans genetically and physiologically [37, 38]. These similarities and differences between mouse and man in relation to studies on aging have been extensively reviewed [15, 3942].

To replicate the pathology of AD in humans, several animal models of AD pathology have been developed. These mouse models have been useful to study the mechanisms involved in the progression of AD and to predict outcomes from pharmacological interventions. No animal model fully replicates the pathogenesis and the cognitive deficits observed in human AD and therefore it is important to understand both the utility and limitations of particular animal models.

According to the recent NIA-AA sponsored consensus reports on three defined stages in a clinical continuum for AD including preclinical and mild cognitive impairment and dementia, the latter is related to the presence and extent of neuropathological changes of AD patients observed at autopsy [43, 44]; we present here these neuropathological changes in healthy aging in mice. Our results suggest that these changes could be affecting the normal vision in AD patients as it has been previously reported.

Although the mouse might not be the perfect model for studying aging, its use as a model of mammalian biology will contribute to gaining important insights into the pathobiology of different diseases, fundamental processes involved in aging, and the relationship between aging and AD. Besides, the validation of these models is totally necessary for a better understanding of the effects of healthy aging and AD on vision loss to translate these advances to humans.

5. Conclusions

Our results show a significant deposition of Aβ42 peptide and overexpression of other AD markers such as p-TAU and GFAP in the VC of WT 25-month-old mice.

We suggest that the overexpression of presenilin-2 observed in our experiments may be one of the first mechanisms involved in beta-amyloid overproduction in our model and that the mechanisms related to neuronal degeneration downstream of Aβ42 accumulation could include membrane-associated oxidative stress, altered Ca2+ homeostasis, altered energy metabolism, and activation of apoptosis. These findings suggest roles for an alteration of immune responses in the aging process.

Our results demonstrate that aging is possibly related to the activation of the amyloidogenic pathway, which induces Aβ42 overproduction and intracellular accumulation in visual cortex cells; furthermore, we suggest that Aβ42 accumulation affects several important mechanisms to initialize neurodegenerative processes, such as those occurring in AD, and could be related to vision loss.

Our results aid to understand the correlation between aging and the development of neurodegenerative diseases such as AD, but additional studies are needed to further investigate the effect of the Aβ42 peptide on the VC and the retina.

Conflicts of Interest

The authors declare that there are no conflicts of interest.


This work is supported by Asociación para Evitar la Ceguera en México, “Hospital Dr. Luis Sanchez Bulnes” IAP. Thanks are due to Mariana Reyes Peña for technical support.


  1. A. Wimo, L. Jonsson, and B. Winblad, “An estimate of the worldwide prevalence and direct costs of dementia in 2003,” Dementia and Geriatric Cognitive Disorders, vol. 21, no. 3, pp. 175–181, 2006. View at: Publisher Site | Google Scholar
  2. J. M. Rubio-Perez and J. M. Morillas-Ruiz, “A review: inflammatory process in Alzheimer's disease, role of cytokines,” The Scientific World Journal, vol. 2012, Article ID 756357, 15 pages, 2012. View at: Publisher Site | Google Scholar
  3. L. E. Hebert, P. A. Scherr, J. L. Bienias, D. A. Bennett, and D. A. Evans, “Alzheimer disease in the US population: prevalence estimates using the 2000 census,” Archives of Neurology, vol. 60, no. 8, pp. 1119–1122, 2003. View at: Publisher Site | Google Scholar
  4. V. W. Henderson, “Estrogen-containing hormone therapy and Alzheimer's disease risk: Understanding discrepant inferences from observational and experimental research,” Neuroscience, vol. 138, no. 3, pp. 1031–1039, 2006. View at: Publisher Site | Google Scholar
  5. L. F. Hernández-Zimbrón and S. Rivas-Arancibia, “Deciphering an interplay of proteins associated with amyloid β 1–42 peptide and molecular mechanisms of Alzheimer's disease,” Reviews in the Neurosciences, vol. 25, no. 6, pp. 773–783, 2014. View at: Publisher Site | Google Scholar
  6. G. K. Gouras, J. Tsai, J. Naslund et al., “Intraneuronal Aβ42 accumulation in human brain,” The American Journal of Pathology, vol. 156, no. 1, pp. 15–20, 2000. View at: Publisher Site | Google Scholar
  7. C. Haass and D. J. Selkoe, “Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide,” Nature Reviews Molecular Cell Biology, vol. 8, no. 2, pp. 101–112, 2007. View at: Publisher Site | Google Scholar
  8. L. Hernández-Zimbrón and F. Selva Rivas-Arancibia, “Deciphering an interplay of protein associated amyloid beta peptide 1-42 and molecular mechanism of Alzheimers disease,” Reviews in Neurosciences, p. 25, 2014. View at: Google Scholar
  9. K. Chiu, T.-F. Chan, A. Wu, I. Y.-P. Leung, K.-F. So, and R. C.-C. Chang, “Neurodegeneration of the retina in mouse models of Alzheimer's disease: what can we learn from the retina?” Age, vol. 34, no. 3, pp. 633–649, 2012. View at: Publisher Site | Google Scholar
  10. X. Liu and G. Hajnoczky, “Ca2+-dependent regulation of mitochondrial dynamics by the Miro-Milton complex,” International Journal of Biochemistry and Cell Biology, vol. 41, no. 10, pp. 1972–1976, 2009. View at: Publisher Site | Google Scholar
  11. A. Kauppinen, J. J. Paterno, J. Blasiak, A. Salminen, and K. Kaarniranta, “Inflammation and its role in age-related macular degeneration,” Cellular and Molecular Life Sciences, vol. 73, no. 9, pp. 1765–1786, 2016. View at: Publisher Site | Google Scholar
  12. H. Yin, L. Chen, X. Chen, and X. Liu, “Soluble amyloid β oligomers may contribute to apoptosis of retinal ganglion cells in glaucoma,” Medical Hypotheses, vol. 71, no. 1, pp. 77–80, 2008. View at: Publisher Site | Google Scholar
  13. M. Pinazo-Duran, R. Gallego-Pinazo, and J. J. García-Medina, “Oxidative stress and its downstream signaling in aging eyes,” Clinical Interventions in Aging, vol. 9, pp. 637–652, 2014. View at: Publisher Site | Google Scholar
  14. A. Martorana, M. Bulati, S. Buffa et al., “Immunosenescence, inflammation and Alzheimer’s disease,” Longevity & healthspan, vol. 1, no. 1, p. 8, 2012. View at: Google Scholar
  15. K. S. Krabbe, M. Pedersen, and H. Bruunsgaard, “Inflammatory mediators in the elderly,” Experimental Gerontology, vol. 39, no. 5, pp. 687–699, 2004. View at: Publisher Site | Google Scholar
  16. H. Bruunsgaard, “The clinical impact of systemic low-level inflammation in elderly populations. With special reference to cardiovascular disease, dementia and mortality,” Danish Medical Bulletin, vol. 53, no. 3, pp. 285–309, 2006. View at: Google Scholar
  17. M. de Martinis, C. Franceschi, D. Monti, and L. Ginaldi, “Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity,” FEBS Letters, vol. 579, no. 10, pp. 2035–2039, 2005. View at: Publisher Site | Google Scholar
  18. G. Candore, G. Colonna-Romano, C. R. Balistreri et al., “Biology of longevity: Role of the innate immune system,” Rejuvenation Research, vol. 9, no. 1, pp. 143–148, 2006. View at: Publisher Site | Google Scholar
  19. T. Wyss-Coray, “Ageing, neurodegeneration and brain rejuvenation,” Nature, vol. 539, no. 7628, pp. 180–186, 2016. View at: Publisher Site | Google Scholar
  20. L. F. Hernández-Zimbrón, E. Gorostieta-Salas, M. L. Díaz-Hung, R. Pérez-Garmendia, G. Gevorkian, and H. Quiroz-Mercado, “Beta Amyloid Peptides: Extracellular and Intracellular Mechanisms of Clearance in Alzheimers Disease,” in In Update on Dementia. InTech, 2016. View at: Google Scholar
  21. J. Yao, S. Chen, Z. Mao, E. Cadenas, and R. D. Brinton, “2-deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease,” PLoS ONE, vol. 6, no. 7, Article ID e21788, 2011. View at: Publisher Site | Google Scholar
  22. F. M. LaFerla, K. N. Green, and S. Oddo, “Intracellular amyloid-β in Alzheimer's disease,” Nature Reviews Neuroscience, vol. 8, no. 7, pp. 499–509, 2007. View at: Publisher Site | Google Scholar
  23. L. F. Hernandez-Zimbron, J. Luna-Muñoz, R. Mena et al., “Amyloid-β peptide binds to cytochrome C oxidase subunit 1,” PLoS ONE, vol. 7, no. 8, Article ID e42344, 2012. View at: Publisher Site | Google Scholar
  24. L. X. Zhang and X. H. Zhang, “The -secretasecomplex:from structuretofunction,” Front. Cell. Neuroscience, 2014. View at: Publisher Site | Google Scholar
  25. L. F. Hernandez-Zimbron and S. Rivas-Arancibia, “Oxidative stress caused by ozone exposure induces β-amyloid 1–42 overproduction and mitochondrial accumulation by activating the amyloidogenic pathway,” Neuroscience, vol. 304, pp. 340–348, 2015. View at: Publisher Site | Google Scholar
  26. K. J. Young and J. P. Bennett, “The mitochondrial secret(ase) of Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 20, no. 2, pp. S381–S400, 2010. View at: Publisher Site | Google Scholar
  27. D. A. Butterfield and D. Boyd-Kimball, “Amyloid β-peptide(1-42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain,” Brain Pathology, vol. 14, no. 4, pp. 426–432, 2004. View at: Google Scholar
  28. X. Huang, R. D. Moir, R. E. Tanzi, A. I. Bush, and J. T. Rogers, “Redox-active metals, oxidative stress, and Alzheimer's disease pathology,” Annals of the New York Academy of Sciences, vol. 1012, pp. 153–163, 2004. View at: Publisher Site | Google Scholar
  29. M. Blurton-Jones and F. M. LaFerla, “Pathways by which Aβ facilitates tau pathology,” Current Alzheimer Research, vol. 3, no. 5, pp. 437–448, 2006. View at: Publisher Site | Google Scholar
  30. A. Demuro, I. Parker, and G. E. Stutzmann, “Calcium signaling and amyloid toxicity in Alzheimer disease,” The Journal of Biological Chemistry, vol. 285, no. 17, pp. 12463–12468, 2010. View at: Publisher Site | Google Scholar
  31. P. S. Aisen, J. Cummings, and L. S. Schneider, “Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease,” Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 3, Article ID a006395, 2012. View at: Publisher Site | Google Scholar
  32. L. Crews and E. Masliah, “Molecular mechanisms of neurodegeneration in Alzheimers disease,” molecular genetics, p. q160, 2010. View at: Google Scholar
  33. M. Tobo, “Immunohistochemical study of gliosis in the brain of aged and patients with dementia,” Fukuoka Acta Medica, vol. 75, no. 2, pp. 72–88, 1984. View at: Google Scholar
  34. J.-P. Coppé, C. K. Patil, F. Rodier et al., “Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor,” PLoS Biology, vol. 6, no. 12, pp. 2853–2868, 2008. View at: Google Scholar
  35. A. Salminen, J. Ojala, K. Kaarniranta, A. Haapasalo, M. Hiltunen, and H. A. Soininen, “Astrocytes in the aging brain express characteristics of senescence-associated secretory phenotype,” European Journal of Neuroscience, vol. 34, no. 1, pp. 3–11, 2011. View at: Publisher Site | Google Scholar
  36. K. M. Rodrigue, K. M. Kennedy, and D. C. Park, “Beta-amyloid deposition and the aging brain,” Neuropsychology Review, vol. 19, no. 4, pp. 436–450, 2009. View at: Publisher Site | Google Scholar
  37. N. L. Nadon, “Aged rodents for biogerontology research,” Handbook of Models for Human Aging, pp. 393–401, 2006. View at: Publisher Site | Google Scholar
  38. M. S. Boguski, “The mouse that roared,” Nature, vol. 420, no. 6915, pp. 515-516, 2002. View at: Publisher Site | Google Scholar
  39. V. Vanhooren and C. Libert, “The mouse as a model organism in aging research: Usefulness, pitfalls and possibilities,” Ageing Research Reviews, vol. 12, no. 1, pp. 8–21, 2013. View at: Publisher Site | Google Scholar
  40. J. T. Eppig, J. E. Richardson, J. A. Kadin, M. Ringwald, J. A. Blake, and C. J. Bult, “Mouse Genome Informatics (MGI): reflecting on 25 years,” Mammalian Genome, vol. 26, no. 7-8, pp. 272–284, 2015. View at: Publisher Site | Google Scholar
  41. M. A. Bogue, L. L. Peters, B. Paigen et al., “Accessing data resources in the mouse phenome database for genetic analysis of murine life span and health span,” Journals of Gerontology - Series A Biological Sciences and Medical Sciences, vol. 71, no. 2, pp. 170–177, 2016. View at: Publisher Site | Google Scholar
  42. C. Pettan-Brewer, M. Treuting, and P., “Practical pathology of aging mice,” Pathobiology of Aging Age-related Diseases, vol. 1, no. 1, p. 7202, 2011. View at: Publisher Site | Google Scholar
  43. B. T. Hyman, C. H. Phelps, T. G. Beach et al., “National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease,” Alzheimer's and Dementia, vol. 8, no. 1, pp. 1–13, 2012. View at: Publisher Site | Google Scholar
  44. MA. Ray, NA. Johnston, S. Verhulst, RA. Trammell, and LA. Toth, “Identification of markers for imminent death in mice used in longevity and aging research,” in Journal of the American Association for Laboratory Animal Science, vol. 49, pp. 282–288, 2010. View at: Google Scholar

Copyright © 2017 Luis Fernando Hernández-Zimbrón et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

1595 Views | 416 Downloads | 4 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.